Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (NASDAQ: COCP) has announced a reprioritization of its clinical development activities due to the impact of the COVID-19 pandemic, focusing on its preclinical COVID-19 program. The company continues its collaboration with Merck on influenza A/B antiviral agents, which may yield up to $156 million in milestone payments. However, supply chain disruptions have delayed the influenza A virus program. The company is progressing in its Norovirus program, with proof-of-concept studies expected to conclude in Q4 2020.